Clough Capital Partners’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
Sell
-51,836
Closed -$3.41M 171
2016
Q3
$3.41M Buy
51,836
+271
+0.5% +$17.7K 0.18% 113
2016
Q2
$3.11M Sell
51,565
-44,544
-46% -$2.59M 0.17% 122
2016
Q1
$5.41M Sell
96,109
-106,643
-53% -$6.41M 0.26% 103
2015
Q4
$13.8M Buy
202,752
+118,092
+139% +$7.74M 0.64% 53
2015
Q3
$5.39M Buy
+84,660
New +$5.57M 0.23% 92

Other funds holding AZN

Clough Capital Partners's AZN Position: Q4 2016 in Review

Clough Capital Partners sold out of AstraZeneca (AZN) in Q4 2016, closing a stake of 51,836 shares — an estimated $3.41M sold.

Clough Capital Partners first reported a position in AZN in Q3 2015 and held it in 5 quarters. The position peaked at $13.8M in Q4 2015. 450 funds tracked by Wall St. Rank hold AZN as of Q4 2016.

  • Clough Capital Partners reported no remaining AstraZeneca position as of Q4 2016 after selling out during the quarter.
  • Clough Capital Partners sold 51,836 AstraZeneca shares in Q4 2016, an estimated $3.41M.
  • Clough Capital Partners first reported a position in AstraZeneca in Q3 2015 and held it in 5 quarters.
  • Clough Capital Partners's AstraZeneca position peaked at $13.8M in Q4 2015.
  • 450 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2016.

Based on Clough Capital Partners's 13F filing for Q4 2016, filed 14 Feb 2017.